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Abstract 
 
Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis in 
animal models and elevated risk for a number of human cancers.  Here we found that 
CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic 
inactivation of retinoic acid (RA), the most active vitamin A derivative, is highly expressed in 
42% (27/65) of primary breast cancers.  We also demonstrated that enhanced expression of 
CYP26A1 suppresses cellular responses to anoikis and consequently promotes anchorage 
independent growth.  This transformed phenotype was sufficient to markedly increase 
tumorigenic and metastatic potential.  Suppression of CYP26A1 significantly reversed 
CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular 
RA status and tumorigenicity.  Our observations provide strong evidence for oncogenic and 
cell survival properties of CYP26A1 in carcinogenesis, and suggest mechanisms whereby 
VAD might promote cancer development. 
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Introduction 
 
 Vitamin A is important for health.  The vitamin A metabolite, all-trans retinoic acid 
(atRA) plays essential roles in formation and maintenance of tissues, stemming from its 
potency as a regulator of cell proliferation, differentiation, and apoptosis.  While essentially 
all cell types express nuclear RA receptors (RA nuclear receptors, RARs, and retinoid-X-
receptors, RXRs) and can potentially respond to RA to positively or negatively regulate 
expression of RA target genes (Chambon, 1996), cellular responsiveness is determined by the 
bioavailability of RA.  This is regulated by the vitamin A nutritional status and the 
coordinated balance between RA biosynthesis and catabolism.  RA-catabolizing cytochrome 
P450 enzymes (CYP26A1, B1, and C1) are specifically involved in the metabolic 
inactivation of RA, and thus limit RA bioavailability of the cell by restricting RA access to 
transcriptional machinery by converting RA to biologically inactive metabolites (White et al, 
1997; Abu-Abed et al, 2001; Petkovich, 2001; Osanai and Petkovich, 2005). 
 Early studies of retinal deficiency on animals have demonstrated a plausible 
association between vitamin A deficiency (VAD) and carcinogenesis (Wolbach and Howe, 
1925); however, the underlying mechanisms explaining how VAD might contribute to the 
high incidence of cancer and increased susceptibility to carcinogenic insult remain to be 
defined.  Despite the fact that the CYP26 enzymes may play a similar but separate role in 
limiting the consequences of fluctuations in nutritional vitamin A, the possibility that 
pathological conditions such as cancer might involve aberrant expression of CYP26A1 has 
recently emerged from several studies.  Accumulating evidence has shown that enhanced RA 
catabolic activity has been observed in various types of cancer and elevated CYP26A1 
expression has been detected in a number of cancer cell types (Sonneveld et al, 1998; Van 
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heusden et al, 1998; Shelton et al, 2006; Chang et al, 2008).  On the other hand, our previous 
study has demonstrated that the cells expressing CYP26A1 gain significant resistance to 
apoptosis due to the state of reduced bioavailability caused by metabolic inactivation of RA 
(Osanai and Petkovich, 2005).  Although the consequence of elevated CYP26A1 activity in 
tumor cells is not clear, clinical observations support the possibility that CYP26A1-mediated 
catabolism could be involved in abrogating the beneficial tumor suppressive effects of 
endogenous RA and the optimal therapeutic efficacy of exogenous RA (Fenaux and Degos, 
1997; Kizaki et al, 1997).  Conversely, numerous clinical studies have provided support for 
use of RA in the treatment of malignancies and premalignant lesions, as well as for 
chemoprevention (Lotan, 1996; Altucci and Gronemeyer, 2001).  While a relationship 
between cellular RA status and tumorigenesis is compelling, it remains to be clarified 
whether RA depletion through metabolic mechanism might promote tumor development.  
Here we show that CYP26A1-mediated catabolism of RA results in a state of functional 
VAD that can contribute to carcinogenic processes. 
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Results 
 
Primary breast cancers overexpress CYP26A1 
Several investigators have revealed that deregulated overexpression of CYP26A1 could be 
detected in a number of cancer cell types, including breast carcinomas (Sonneveld et al, 1998; 
Van heusden et al, 1998).  First, we investigated the expression of CYP26A1 in breast 
cancers with tissue microarray slides.  We found only weak positive reactivity in ducts and 
lobules within normal breast tissues (Figure 1a, Supplementary figure 1), whereas distinct 
strong cytoplasmic staining was observed in 23 of 50 (46%) breast carcinomas (Figures 1b-d, 
Supplementary table 1).  In addition, metastatic carcinomas had significantly higher 
CYP26A1 expression, suggesting a potential role of CYP26A1 in tumor development. 
 Importantly, strong positive staining was also observed in 27 of 65 (42%) surgically 
resected breast cancer specimens (Supplementary table 2).  Kaplan-Meier analysis of these 
cases suggested that high expression of CYP26A1 might be associated with decrease in both 
disease-free (p=0.011) and overall survival (p=0.026).  However, no direct proof exists to 
support this observation mainly due to limited numbers of a well-characterized series of 
patients with breast cancer with a long-term follow-up.  We did not observe any increase of 
gene copy number for the CYP26A1 locus by fluorescent in situ hybridization analyses (data 
not shown).  Consistent with these observations, transcriptional complexity should be noted 
for understanding the regulatory mechanism of CYP26A1 overexpression during the 
carcinogenic scenario (Loudig et al, 2000; Loudig et al, 2005). 
 
Establishment of CYP26A1-overexpressing cells 
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To deplete cells of RA in vitro, we generated independent two CYP26A1 constitutively 
overexpressing pools of AC2M2 cells, metastatic variant of breast cancer cell line, designated 
AC2M2-CYP26#1 and -CYP26#2.  Previous reports demonstrated that certain cell lines such 
as MCF-7 show inducible endogenous CYP26A1 expression after atRA treatment (White et 
al, 1997), but AC2M2 cells transfected with an empty vector did not express CYP26A1, with 
or without atRA pretreatment.  In contrast, AC2M2-CYP26A1#1 and -CYP26A1#2 cells 
abundantly expressed CYP26A1 mRNA at similar levels (Figure 2a).  CYP26A1#2 cells 
expressed a slightly higher CYP26A1 protein level but with significantly higher catabolic 
activity than CYP26A1#1, in both cases inhibitable by prior transfection of CYP26A1-
specific small-interfering RNA (siRNA; Figures 2b and c). 
 
Altered gene-expression profile provides oncogenic and cell survival properties in CYP26A1 
expressing cells 
We next assayed the gene-expression profiles of control cells and CYP26A1 transfectants 
using cancer pathway-specific cDNA microarrays to examine the possibility that mRNA 
induced or suppressed by CYP26A1 expression was responsible for the tumor pathology 
(Figure 3).  While ER-positive breast cancers generally have a better prognosis and are often 
responsive to anti-estrogen therapy, ER-negative breast cancers are more aggressive and 
unresponsive to anti-estrogens.  Surprisingly, changes in patterns of gene expression were 
similar between ER-positive MCF-7 clones and the mixed populations of ER-negative 
AC2M2 transfectants (Figure 3a).  CYP26A1 expression affects regulation of an extensive 
range of oncogenic pathways including oncogenes, tumor suppressor genes, and components 
of the apoptotic machinery, as well as death receptor family members (Figures 3b and c).  
Although apoptosis is linked with deregulated cell cycle events and impaired DNA damage 
 7
repair systems (Evan and Vousden, 2001), an underlying part of these abnormalities may be 
associated with the RA status in the cells based on the changes in gene expression associated 
with this mechanism such as p16Ink4 and chk2.  Signaling through the Akt and mitogen-
activated protein kinase (MAPK) pathways may be also modulated by CYP26A1.  CYP26A1 
expression may affect not only the wide range of signaling pathways in the cell but also the 
tumor microenvironment and tumor cell-interstitial cell interactions, demonstrating by the 
altered expression of cell adhesion molecules such as integrins.  Further evidence includes the 
possible association of gene families involved in tumor cell invasion and metastasis such as 
uPA, and angiogenesis such as VEGF.  These gene-expression alterations suggest that many 
of the genes involved in cancer pathways are modulated to favor cell survival when 
CYP26A1 is overexpressed. 
 
CYP26A1 overexpression provides increased resistance to anoikis 
Evasion of apoptosis is a hallmark of cancer and resistance to anoikis (apoptosis resulting 
from loss of cell-matrix interaction) may be a predominant contributor to neoplastic 
progression (Evan and Vousden, 2001; Gozani et al, 2002).  Our previous studies showed 
that various cell lines overexpressing CYP26A1 gain significant resistance to a number of 
apoptogenic stimuli (Osanai and Petkovich, 2005).  Consistent with the ability of CYP26A1 
to suppress apoptosis, we verified that CYP26A1 overexpression provided the given cells 
with decreased susceptibility to a number of differently acting apoptogens, without cell type 
specificity (Supplementary figure 2).  Therefore, we next examined the possibility whether 
CYP26A1 overexpression suppresses anoikis.  As hypothesized, the apoptotic sensitizing 
effect of atRA increased the sensitivity of anoikis in control cells, whereas CYP26A1 
transfectants showed significant resistance even in the presence of atRA over time (Figure 
 8
4a).  This decreased apoptotic sensitivity of AC2M2-CYP26A1#2 cells was partially but 
significantly abrogated by CYP26A1-specific siRNA-mediated silencing (Figure 4b), 
suggesting catalytic activity of the enzyme to be important for its anti-apoptotic effects.  In 
addition, CYP26A1-expressing cells demonstrated an accelerated cell growth rate relative to 
the AC2M2 controls.  Although we observed that the basal levels of apoptosis were different 
between controls and CYP26A1 transfectants (Figures 4a and b), there was evidence that 
normal FBS contained a physiological concentration of atRA, which is known to be sufficient 
to switch on the RA-driven transcriptional machinery (Osanai and Petkovich, 2005).  This is 
also explained by the observation that the basal level of apoptosis was not changed in the 
event of CYP26A1 overexpression in medium supplemented with endogenous RA-depleted 
(e.g. charcoal-dextran treated) FBS (data not shown).  Importantly, endogenous CYP26A1 
expression also provided lower sensitivity to anoikis, allowing exclusion of the possibility 
that the forced expression of CYP26A1 resulted in possible unidentified artifacts (Figure 4c).  
We next determined by immunoblotting the protein levels of cleaved caspase-3, a primary 
executioner of apoptosis.  No activated caspase-3 was detected in any of the cells when 
grown on adhesive dishes, but it was produced by control cells when they were brought into 
suspension (Figure 4d).  By contrast, cleaved caspase-3 production was dramatically 
suppressed by CYP26A1 transfection.  These results indicate that CYP26A1 effectively 
suppresses the apoptotic sensitivity of the cells. 
 
CYP26A1 is predominantly associated with MAPK signaling 
To examine the signal transduction pathways involved in the CYP26A1-mediated apoptotic 
resistance, we used various specific kinase inhibitors.  A MAPK inhibitor (PD98059) 
significantly restored the sensitivity to anoikis that was suppressed by CYP26A1, whereas 
 9
other inhibitors such as a p38 MAPK inhibitor (SB203580) and a phosphoinositide-3-kinase 
(PI3K) inhibitor (LY294002) had significant but much less marked effects when compared 
with that by PD98059 (Figure 4e).  Consistent with this, the protein level of pMAPK was 
increased in AC2M2-CYP26A1#2 cells; this upregulation was significantly abrogated by the 
treatment with CYP26A1-specific siRNA, suggesting that CYP26A1 is predominantly 
associated with the MAPK signaling pathway. 
 
CYP26A1 overexpression enhances tumorigenic potency in vitro 
We next evaluated the ability of tumor cells to grow under anchorage independent growth 
conditions, a measure of cell transformation.  Shifting the cells from adhesive to non-
adhesive dishes resulted in massive cell death in control cells, whereas CYP26A1 expression 
effectively suppressed anoikis and contributed to formation of large spheroid-like aggregates 
in suspension (Figure 5a).  Similarly, although both of control cells and CYP26A1 
transfectants showed anchorage independent growth in soft agar, CYP26A1-expressing cells 
grew as colonies more than 6-fold in number, a property not observed in the AC2M2 controls 
(Figure 5b).  In addition, CYP26A1 allowed anchorage independent growth, forming 
significantly larger colonies relative to the parental control.  In particular, AC2M2-
CYP26A1#2 cells that exhibited higher RA catabolic activity than AC2M2-CYP26A1#1 
produced larger colonies (Figure 5c).  Transfection with CYP26A1-specific siRNA partially 
but significantly abrogated the CYP26A1-mediated increase of colony-forming capabilities, 
being possible to link the expression of CYP26A1 with the observed phenotypes (Figure 5b).  
Partial effects of siRNA primarily might be caused by transient transfection, in which 
expression of the transfected gene decreases with cell division.  If the partial effects of siRNA 
might be due to limitations of transient transfection, this might also affect other data shown in 
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the present study.  Other breast carcinoma cell lines showed similar results, regardless of the 
presence of ER, so that the effect by CYP26A1 was not cell type specific (Figure 5d).  The 
data was also supported by the observation that the cells transfected with deletion mutants of 
CYP26A1 showed a positive correlation between colony forming efficacy in soft agar and the 
catabolic activity of atRA (Supplementary figure 3).  These observations suggest that the 
expression of CYP26A1 potentially contributes to accelerate anchorage-independent growth 
in association with the RA status regulated by metabolic processes in the cells. 
 
 
CYP26A1 mediates enhanced tumorigenicity in vivo and contributes to cancer metastasis 
To address whether CYP26A1 enhances tumorigenicity, we next employed orthotopic 
transplantation in mice.  Expression of CYP26A1 in AC2M2 cells was sufficient to enhance 
in vivo tumorigenicity, causing a markedly accelerated rate of tumor formation in mammary 
fat pads relative to the controls (Figures 6a and b).  The cells comprising CYP26A1-
expressing tumors showed high-grade malignant characteristics, including a lower apoptosis 
and a higher mitotic index, enhanced infiltration into subcutaneous connective tissue with 
small necrotic foci, indicative of rapid tumorigenesis (Figures 6c and d).  These data support 
the possibility that acquisition of CYP26A1-mediated enhanced tumorigenicity is associated 
with RA metabolism in the cells.  Histopathological examination of CYP26A1-
overexpressing AC2M2 cell-derived tumors also revealed more vascular components than 
those derived from controls (Figure 6d).  Interestingly, CYP26A1-expressing AC2M2 cells 
showed significantly higher VEGF expression and this elevated expression could be partially 
downregulated by the treatment with CYP26A1-specific siRNA (Figure 6e).  This 
observation suggests the possible mechanistic link between CYP26A1-mediated degradation 
of RA and angiogenic activity in tumor tissue, which is in good agreement with the evidence 
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that RA is known to have an angiogenesis-inhibiting activity.  Since pathological 
angiogenesis is an important contributing factor in tumor formation and progression, it is 
plausible that enhancement of tumor growth by CYP26A1 could be both the result of effects 
on the tumor cells but also on the tumor microenvironment.  However, the interaction 
between tumor microenvironment and genetic mechanisms influencing tumor angiogenesis 
and growth is complex and is only now beginning to be elucidated.  Consistent with the 
ability of CYP26A1 to suppress anoikis, CYP26A1-transfected AC2M2 cells showed an 
enhanced potential to metastasize to lung and metastases contained fewer apoptotic cells 
(Figure 6f).  These results indicate that CYP26A1-mediated acquired phenotypes such as 
enhanced tumorigenicity and metastatic behaviors are likely associated with the RA 
bioavailability in the cells. 
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Discussion 
 
 Our observations unveil a mechanistic link between RA catabolism and enhanced 
tumorigenicity, implicating CYP26A1 as a possible candidate oncogene.  This is in line with 
earlier studies suggesting that VAD is associated with carcinogenesis (Wolbach and Howe, 
1925), and upregulation of CYP26A1 has recently been shown in a number of cancer cell 
types (Sonneveld et al, 1998; Van heusden et al, 1998; Shelton et al, 2006; Chang et al, 
2008).  If increased RA metabolism is solely responsible for the apoptogen desensitizing 
effect, our results would imply that in a state of RA deficiency, cells may be less susceptible 
to apoptosis following the acquisition of DNA damage.  As a corollary, individuals suffering 
from VAD might be expected to accumulate DNA damage with higher frequency.  This may 
provide a plausible explanation for the increased incidence and higher risk of cancer 
formation and development observed in individuals with VAD.  Epidemiological studies 
showed that an increased incidence of lung cancer has been observed in the individuals with 
VAD, and have pointed to an association between VAD and cancers arising in the uterine 
cervix, oral cavity, and oropharynx, for example (French et al, 2000).  Similarly, ultraviolet 
irradiation induces a functional VAD state in skin that may contribute to skin carcinogenesis, 
suggesting an association between VAD and a high risk of some types of cancer (Wang et al, 
1999). 
 CYP26A1 confers unique cell-survival properties on cells, modulating a wide variety 
of genes to favor cell survival, which results in a selective growth advantage to the cells.  We 
have demonstrated that the intracellular RA status regulated by the expression of CYP26A1 
plays a central role in determining the cellular sensitivity to apoptosis, and a state of reduced 
RA bioavailability suppresses cellular response to proapoptotic or several different inducers 
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of apoptosis (Osanai and Petkovich, 2005).  Consistent with the protective role played by 
CYP26A1 against a broad range of apoptogens, CYP26A1 upregulation effectively affects 
the gene-expression signature already present in tumor cells to potentially generate a wide 
variety of specific and potent pro-survival signals that render cells resistant to anoikis.  In 
view of the multiple signaling pathways, overexpression of CYP26A1 has been shown to lead 
to induction of oncogenes such as c-Myc and epidermal growth factor receptor, repression of 
tumor suppressor genes, and deregulation of cell cycle and DNA repair genes, suggesting a 
gene expression pattern favoring cell survival with antiapoptosis signals (Chang et al, 2008).  
Therefore, it is acceptable to believe that alterations of several signaling pathways due to 
CYP26A1 expression contribute to inactivation of and/or escape from multiple cellular 
transformation events (oncogenic “hits”), eventually enhancing tumor formation and 
progression.  CYP26A1 activation also results in the acquisition of metastatic potency, which 
provides a possible explanation for the aggressive nature of human breast carcinomas that 
overexpress CYP26A1.  There is still a possibility that CYP26A1 overexpression causes 
intracellular RA depletion that drives the cells into highly oncogenic state with induction of 
other known oncogenes.   
 We demonstrated that the suppression of CYP26A1 significantly reversed CYP26A1-
mediated oncogenic characteristics, suggesting a direct link between intracellular RA status 
and tumorigenicity.  Importantly, knockdown experiments were not possible due to the low 
basal CYP26A1 transcript levels in commercially available breast carcinoma cell lines, 
though primary breast carcinomas should have high CYP26A1 expression.  Since our 
preliminary experiment confirmed in MCF-7 cells for which we have well-established 
profiles of CYP26A1 expression and inducibility, we used MCF-7 cells treated with atRA to 
show that suppression of endogenous CYP26A1 provided increased sensitivity to apoptosis.  
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There remains a possibility that forced expression of CYP26A1 may have some additional 
interesting but as yet uncharacterized effects on the cells.  To exclude that forced expression 
of CYP26A1 can lead to nonspecific effects on the cells, it is necessary to use conditional 
knockout approaches to completely assess CYP26A1 function, since total knockout of 
CYP26A1 shows embryonic lethality (Abu-Abed et al, 2001).  Interestingly, the abrogation 
of the functional effects of CYP26A1 overexpression by specific inhibitors of CYP26A1, 
which are not yet commercially available, would provide a detailed molecular mechanism 
explaining oncogenic and cell survival properties of CYP26A1. 
 The CYP26A1 enzyme primarily protects cells and tissues from exposure to RA, 
playing important roles in finely regulating RA distribution in tissues during embryogenesis.  
Given the pleiotropic activity of RA, it is not surprising that CYP26A1 expression can affect 
a vast array of physiological pathways in regulating various independent signaling molecules 
associated with the tumorigenic events.  Indeed, this is strongly suggested by CYP26A1 
knockout animals, which exhibit severe caudal regression syndrome and embryonic lethality 
(Abu-Abed et al, 2001).  Conversely, recapitulation of CYP26A1 expression in cancer cells 
would provide a selective growth advantage to these cells and thus evade normal apoptotic 
mechanisms.  Therefore, strategies that decrease activity of CYP26A1 may be an important 
means of increasing the sensitivity of cancer cells to proapoptotic therapies.  We believe that 
specific drug-mediated inactivation of CYP26A1 may have a notable impact on malignant 
potential of human tumors with overexpressed CYP26A1, and these results show its potential 
feasibility of CYP26A1-inhibitory cancer therapies. 
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Materials and methods 
 
Patient samples 
We used archival formalin-fixed, paraffin-embedded tissue specimens, prepared from 
surgically resected breast carcinomas.  Informed consent was obtained from patients for 
pathological assessment of their surgical specimens.  Histological type of breast cancer was 
classified by the WHO guidelines (Tavassoli and Devilee, 2003), and pathological tumor 
stage was defined according to the TNM classification of malignant tumors of the 
International Union Against Cancer (Sobin and Wittekind, 2002).  Since patients with no 
further follow-up information were excluded from the list in this study, all patients were 
followed up for a minimum of 6 years. 
 
Immunohistochemistry 
After deparaffinization and antigen retrieval, 4 µm tissue sections and tissue microarray 
slides (Super Bio Chips, Seoul, Korea) were incubated overnight at 4 ºC with primary 
antibodies against CYP26A1 (Santa Cruz Biotechnologies, Santa Cruz, CA), Ki67 (Dako, 
Glostrup, Denmark), or CD34 (Dako).  The sections were then reacted with EnVision (Dako) 
for 30 min at room temperature.  We routinely used positive and negative controls, and 
confirmed the results in independent duplicate analyses.  Positive staining was graded as 
percentage of tumor cells stained: 3+ (strong), staining in >50% of the cells; 2+ (moderate), 
staining in >25% of the cells, 1+ (low), staining in > 5% of the cells, 0 (negative), no or faint 
staining in <5% of the cells.  We considered CYP26A1 expression to be strong with staining 
grades 2+ or 3+, and considered a test result of 0 and 1+ as negative. 
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Cell line 
All cell lines were maintained in DMEM (Life Technologies, Grand Island, NY) 
supplemented with 10% FBS (Life Technologies).  AC2M2 cell line is a metastatic variant of 
SP1 breast carcinoma cells, isolated from a mammary intraductal adenocarcinoma which 
arose spontaneously in an 18-month-old CBA/J female retired breeder (Elliott et al, 1988).  
AC2M2 and MDA-MB-231 cells are ER-negative, and MCF-7, ZR75-1, and T-47D cells are 
ER-positive breast carcinoma lines. 
 
Construction of expression vectors and transfection 
Full-length CYP26A1 cDNA (GeneBank accession number, NM_000783) was amplified by 
reverse transcription (RT)-PCR from total RNA extracted from MCF-7 cells pretreated with 
atRA (White et al, 1997).  After subcloning by a TA cloning (Invitrogen, Carlsbad, CA), the 
cDNA fragment of CYP26A1 was ligated into the pcDNA3.1(-) expression vector (Clontech, 
Palo Alto, CA), yielding pcDNA3.1(-)-CYP26A1.  Likewise, we also made a number of 
deletion mutants (Supplementary figure 3). 
We transfected cells with 5 µg of each plasmid using the FuGene6 transfection 
reagent (Roche, Basel, Switzerland) to generate stable transfectants.  Selection of clones was 
carried out in AC2M2 cells in the presence of 0.8 mg/ml G418 (Sigma, St. Lois, MO).  After 
15 days of selection, the drug resistant clones were picked up and screened for their RA 
catabolic activity.  Our preliminary experiments showed that observed phenotypes of the cells 
in the event of CYP26A1 overexpression were similar but not exactly the same with at least 3 
different independent clones.  Therefore, cells were equally mixed to establish stably 
transfected cell lines to avoid possible clonal variation and exclude the possibility that 
 17
cloning procedures selected for a more tumorigenic phenotype.  We transfected an empty 
vector as a control. 
Two concentrations of siRNA targeted to CYP26A1 (25 or 50 nM; Santa Cruz) were 
also transfected into cells using the FuGENE6 reagent 48 h prior to the treatment, with or 
without another reagent such as atRA for 24 h.  Negative control siRNA was used as control 
to demonstrate that the transfection itself had no specific effects on gene expression. 
 
Anoikis induction 
AC2M2 cells were prevented from adhering to the plastic of cell culture dishes in order to 
induce anoikis (Osanai et al, 2006).  In some experiments, atRA (10 nM-2.5 M, 0.1 M as a 
default concentration; Sigma), which is an apoptotic sensitizer (Osanai and Petkovich, 2005), 
a MAPK inhibitor (PD98059, 50 M, Sigma), p38 MAPK inhibitor (SB203580, 20 M, 
Sigma), or PI3K inhibitor (LY294002, 20 M, Sigma) were added. 
 MCF-7 cells were also subjected to this assay.  Our preliminary experiment confirmed 
that MCF-7 cells constitutively expressed CYP26A1 in medium supplemented with 10% FBS, 
and atRA could strongly induce CYP26A1 levels in MCF-7 cells.  Cells were transfected 
with CYP26A1-specific siRNA (50 nM) 48 h prior to the apoptotic stimulation, followed by 
induction of anoikis in serum-starved fresh medium in the presence of 1 M atRA. 
 
Soft agar assay 
Soft agar assays were carried out in 6 cm dishes to assess colony formation in three-
dimensions (Osanai et al, 2006).  Cells were incubated during the time until either cells of 
control or its transfectant grew more than approximately 200 m in diameter.  Colonies 
developing on cell culture dishes in soft agar suspension were scored using phase contrast 
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microscopy by counting colony numbers under low magnification (x 100) in 10 separate 
arbitrary fields in each plate.  Cell clusters more than approximately 50 m in diameter were 
defined as positive results in the soft agar assay.  In the quantitative analysis, the number of 
colonies formed from control cells was defined as 100%. 
 
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay  
Multicellular spheroids and tumor tissues developing in mice were fixed with 70% methanol 
and embedded in 1% agar or paraffin.  TUNEL assays were performed to visualize the 
apoptotic cells using an In Situ Cell Death Detection Kit (Roche).  We also ran the staining 
procedure without TdT as a negative control.  The cells of interest were scored under a light 
microscope by counting the number of cells under low magnification (x 100) in 10 randomly 
selected fields in each section. 
 
Western blot analysis 
Whole cell lysates, each with 20 g of denatured proteins, were run on 12-15% SDS-
polyacrylamide gels and electroblotted onto nitrocellulose filters.  These were immunoblotted 
with antibodies against CYP26A1 (Santa Cruz), pMAPK (Cell Signaling, Beverly, MA), 
ERK1/2 (Promega, Madison, WI), and -actin (Santa Cruz) proteins.  The filters were then 
reacted with corresponding peroxidase-labeled secondary antibodies, and immunoreactions 
were visualized using an enhanced chemiluminescence system (GE Healthcare, Buckingham, 
UK).  For densitometric analyses, signals were quantitated using Scion Image 1.62 (Scion 
Corporation, Frederick, MD), and the level in control cells was defined as 100%.  To show 
the signal intensity of pMAPK/ERK1/2, signals of pMAPK (p44) were normalized to the 
expression of ERK1/2 (p44) in each sample. 
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Semiquantitative RT-PCR and Southern blot analysis 
Total RNA (1 g) extracted using TRIzol (Invitrogen) was reverse-transcribed using M-
MuLV reverse transcriptase (Invitrogen).  For analysis of gene expression, the gene of 
interest was amplified from dilutions of cDNA for up to 40 cycles, and we examined various 
cycling parameters for each PCR experiment to define optimal conditions for linearity to 
allow semiquantitative analysis of signal intensity.  Electrophoresed DNA from the agarose 
gel was transferred to a Hybond N+ nylon membrane overnight (GE Healthcare).  Full-length 
cDNA of each gene was employed as a probe labeled with [32P]dCTP to a specific activity of 
approximately 1 x 109 cpm/g using a  random priming-based cDNA labeling kit (Nippon 
Gene, Tokyo, Japan).  To provide a qualitative control, PCR reactions were also performed 
with primers coding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  Triplicate 
independent PCR reactions were carried out to confirm reproducibility of expression 
quantification. 
 
Tumor growth in vivo 
We injected cells of AC2M2 and its transfectant (10 μl volume of cells/mouse) into 
mammary fat pads of 6 or 7-week-old female mice (CBA/J; Charles River Japan, Yokohama, 
Japan; Osanai et al, 2006).  Animals were euthanized as a function of time when skin 
ulceration of the primary tumor occurred.  We examined the primary tumor and all organs 
including lungs macroscopically for evaluation of tumor and metastases, followed by 
histological evaluation for pulmonary micrometastases.  Tumor angiogenesis was evaluated 
in terms of the CD34-positive microvasculature in tumors developed in mice.  The 
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maintenance and handling of animals were carried out using protocols approved by the 
Animal Care Committee of the University. 
 
cDNA array analysis 
Cancer Pathway Finder Gene Arrays by GEArray (SuperArray, Bethesda, MD) were 
employed to examine the possibility that mRNAs induced or suppressed by CYP26A1 
expression were responsible for changes in the tumor pathology (Osanai and Petkovich, 
2005; Osanai et al, 2006).  The signal intensity of a given gene was normalized to that 
derived from GAPDH on the same membrane and expressed in arbitrary units, in order to 
consider possible variation in RNA quantification between samples.  Gene-expression 
changes caused by CYP26A1 expression were then normalized to the values in control cells. 
 
Statistical analysis 
Statistical analysis was performed using StatView 5.0 software.  Unless otherwise specified, 
all data represent the mean  s.d. of at least 3 independent experiments, each in triplicate 
specimens, and we evaluated experimental results using the paired t test.  Overall survival 
and disease-free periods were examined by the Kaplan-Mayer method with a log rank test to 
assess their significance.  Association between CYP26A1 immunoreactivity and different 
clinicopathological parameters in breast carcinoma was studied using chi-square test.  A p-
value of <0.05 was considered significant. 
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Figure legends 
 
Figure 1.  Enhanced expression of CYP26A1 in breast carcinomas.  (a) CYP26A1 expression 
in ductal (left) and lobular (right) cells of normal breast (arrowheads).  (b) CYP26A1 
overexpression in primary breast carcinomas (Pr) and metastatic breast carcinomas (Mt), but 
not in normal tissues (Nr), using tissue microarray analysis.  (c) Correlation between tissue 
types and staining intensity of positive signals (horizontal bar, mean score).  p<0.05 versus 
score from Nr (a) or Pr (b).  (d) Three representative breast carcinoma cases with strong 
CYP26A1 positivity.  Original magnification: left column, x 4; right column, x 200. 
 
Figure 2.  Establishment of CYP26A1-overexpressing AC2M2 cell lines.  (a) Expression of 
CYP26A1 in independent two cell lines.  (b) RA catabolic assay using 3H-atRA as a substrate.  
Catabolic activity of the CYP26A1 enzyme converts atRA to water-soluble metabolites.  (c) 
Suppressive effect on CYP26A1 expression of CYP26A1-specific siRNA in AC2M2-
CYP26A1#2 cells.  p<0.05, vs. control cells when transfected with CYP26A1 (*) or 
CYP26A1 siRNA (#). 
 
Figure 3.  CYP26A1 affects multiple signaling pathways involved in cancer development.  (a 
and b) Venn diagram showing the number of changes caused by CYP26A1 expression in 
AC2M2 and MCF-7 cells.  Numbers indicate genes increased or decreased by an average of 
≥30% or ≤-30% (n=2) (a).  Overlapping circle indicates gene numbers increased or decreased 
by an average of ≥100% or ≤-100% (n=2), which are also shown in graph in functional gene 
grouping (b).  (c) Verification of the cDNA array results by quantitative RT-PCR and 
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Southern blot analysis in AC2M2 cells.  p<0.05, vs. control cells when transfected with 
CYP26A1 (*). 
 
Figure 4.  Upregulation of CYP26A1 provides increased resistance to anoikis.  (a) DNA 
laddering analysis after plating on a non-adhesive dish to induce anoikis at 24 h postplating.  
(b) TUNEL assay in cell aggregates cultured as spheroids (left), quantitative analysis of 
apoptosis (right), and Ki67 labeling indexes (inset) of cells at day 5.  (c) Increased sensitivity 
to apoptosis in MCF-7 cells on suppression of endogenous CYP26A1.  (d) Immunoblotting 
for cleaved caspase-3 in lysates from AC2M2 cells cultured on adhesive and non-adhesive 
plates for 3 days.  (e) Effects of three types of kinase inhibitors on apoptosis (left), and 
immunoblotting of pMAPK and ERK1/2 (right).  p<0.05, vs. control cells when transfected 
with CYP26A1 (*) or CYP26A1 siRNA (#), and p<0.05, vs. control cells when treated with 
atRA (**) or protein kinase inhibitor (†). 
 
Figure 5.  CYP26A1 overexpression enhances tumorigenicity in vitro.  (a) Large spheroid-
like aggregates formation by CYP26A1-expressing AC2M2 cells.  (b, c, and d) CYP26A1 
promotes colony formation in soft agar in AC2M2 (b, c) and other indicated (d) cells.  
Quantification of colony numbers in CYP26A1-expressing cells (b, d) and representative 
morphology of the colonies (c).  p<0.05, vs. control cells when transfected with CYP26A1 
(*) or  CYP26A1 siRNA (#). 
 
Figure 6. CYP26A1 expression enhances tumorigenic and metastatic properties in vivo.  (a 
and b) Faster growth of CYP26A1-expressing tumors in vivo.  (a) Tumor volume was 
calculated in two dimensions in a time-dependent manner after inoculation of the vector 
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(circle symbol) and CYP26A1-transfected (square symbol) cells in the first (open) and 
second (filled) lines of experiments (control, n=9; CYP26A1#2, n=12 in independent 
duplicate experiments).  (b) Representative tumors developing in mice 18 days postinjection 
(left), and their weights on dissection (right).  (c) Histology of tumors (tm) in mice 
developing from transplanted cells.  Note the invasion (*) of CYP26A1-overexpressing cells 
into surrounding muscle (ms) and fibrous tissue (fb).  (d) Quantitative analyses of tumors 
developing in mice.  (e) VEGF protein levels in AC2M2 cells transfected with or without 
CYP26A1-siRNA.  (f) CYP26A1 overexpression confers increased cancer metastasis to lung.  
Quantitative analysis of lung metastasis in mice following transplantation of AC2M2 cells 
(2.5 x 103 cells/mouse) transfected with vector (n=9) and CYP26A1 (CYP26A1#1, n=12; 
CYP26A1#2, n=12)(left), and apoptotic cells in representative metastatic lesions were 
evaluated by TUNEL assay (right).  Mice were sacrificed after 25.3 days post-inoculation 
with vector-transfected cells and after 16.8 days with CYP26A1 transfected cells.  p<0.05, vs. 
control cells when transfected with CYP26A1 (*) or CYP26A1 siRNA (#), and p<0.05, vs. 
control cells when treated with atRA (**). 
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Legends to Supplementary Figures 
 
Supplementary Figure 1.  The CYP26A1 antibody specifically recognizes CYP26A1 
protein in Cos7 cells that were transiently transfected with cDNA as indicated.  
Immunoblotting was performed 48 h after transfection and equal loading was confirmed by 
β-actin. 
 
Supplementary Figure 2.  CYP26A1 expression protects cells from a broad range of pro-
apoptotic cell stresses in various types of cells.  Cells were transfected with or without 
CYP26A1-specific siRNA (50 nM) 48 h before apoptotic stimulation in vector or CYP26A1-
transfected cells.  (a) Oxidative stress-mediated apoptosis (100 M H2O2 for 24 h) was 
induced in cells as indicated.  (b) Cell death was examined in AC2M2 cells with a number of 
different apoptotic inducers, including H2O2 (100 M for 24 h), heat shock at 42C for 30 
min, etoposide (VP16, 50 M), cisplatin (CDDP, 10 g/ml), and -irradiation (50 or 100 Gy).  
(c) Transient transfection of CYP26A1 is sufficient for suppression of apoptosis.  AC2M2 
(A) or MCF7 (M) cells were transfected with full-length CYP26A1 cDNA 48 h before 
apoptotic stimulation with a number of different apoptotic inducers.  p<0.05, vs. control cells 
when transfected with CYP26A1 (*) or CYP26A1 siRNA (#). 
 
Supplementary Figure 3.  Preferential interaction between RA metabolic activity and 
resistance to apoptosis.  (a) Constructs of deletion mutants to identify the gene locus 
responsible for the apoptotic de-sensitization effect.  Full-length CYP26A1 cDNA (coding 
sequence from 26 to 1519 in nucleotides in GeneBank accession number, NM_000783) was 
denoted as CYP26A126-1519.  Various binding motifs were found in CYP26A1 cDNA using a 
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database search: Fe, 2Fe-2S ferredoxins, iron-sulfur binding region signature, or 4Fe-4S 
ferredoxins, iron-sulfur binding region signature; VW, VWFC domain signature; AN, 
anaphylatoxin domain signature; C, C-terminal cystine knot signature; EGF, EGF-like 
domain signature 1.  Note that most binding signatures are located in N- or C-termini of the 
CYP26A1 cDNA.  (b) Relative catabolic activities of atRA in cells transfected with various 
deletion mutants.  Metabolic activity of AC2M2-CYP26A1#2 cells (CYP26A126-1519) was 
defined as 100%.  (c) Anoikis was induced in cells transfected with various deletion mutants 
with (+) or without (-) 1 μM atRA pretreatment (left), and colony forming efficacies in soft 
agar of AC2M2 cells transfected with various deletion mutants (right).  The number of 
colonies formed from cells transfected with empty vector was defined as 100%.  (d) 
Representative results of colony morphology in soft agar and note the difference in colony 
size.  p<0.05, vs. control cells when transfected with CYP26A1 or CYP26A1 mutants (*).  
p<0.05, vs. control cells when treated with atRA (**). 
 









Supplementary Table 1.  CYP26A1 expression and clinical profiles in breast cancer tissue microarray. 
 
No. Sex Age Organ Diagnosis pTNM Stage LNa ERb PgRc 
 
p53 
 
CYP26A1 
1 F 28 Breast Invasive ductal carcinoma T4cN3cMx IIIC N/Ad + - - 1 
2 F 71 Breast Invasive papillary carcinoma T3N1aM0 IIIA 2/12 + + - 1 
3 F 26 Breast Invasive ductal carcinoma T4bN3aM0 IIIC 22/25 + - - 0 
4 F 43 Breast Invasive ductal carcinoma T4bN2aM0 IIIB 4/13 + + - 1 
5 F 39 Breast Invasive ductal carcinoma T3N0M0 IIB 0/37 - - + 1 
6 F 46 Breast Invasive ductal carcinoma T3N3aM0 IIIC 14/15 + + - 2 
7 F 47 Breast Invasive ductal carcinoma T2N3aM0 IIIC 37/41 - - + 0 
8 M 67 Breast Invasive ductal carcinoma T3N1aM0 IIIA 1/12 + + - 1 
9 F 33 Breast Invasive ductal carcinoma T3N3aM0 IIIC 25/25 + + - 1 
10 F 47 Breast Invasive ductal carcinoma T2N0M0 IIA 0/15 + + - 0 
11 F 49 Breast Invasive lobular carcinoma T2N1aM0 IIB 1/14 - - - 0 
12 F 46 Breast Invasive ductal carcinoma T3N1aM0 IIIA 2/25 + - - 0 
13 F 39 Breast Invasive ductal carcinoma T2N1aM0 IIB 2/19 + - - 2 
14 F 43 Breast Invasive lobular carcinoma T3N3aM0 IIIC 25/25 - - - 2 
15 F 54 Breast  Invasive lobular carcinoma T3N3aM0 IIIC 28/31 + - + 0 
16 F 58 Breast Invasive ductal carcinoma T4bN1aM0 IIIB 1/15 - - - 0 
17 F 37 Breast Invasive ductal carcinoma T2N1aM0 IIB 2/14 + + + 2 
18 F 43 Breast Invasive ductal carcinoma T2N0M0 IIA 0/13 - - + 1 
19 F 51 Breast Ductal carcinoma in situ TisN0M0 0 0/20 + + - 1 
20 F 80 Breast Medullary carcinoma T3N2aM0 IIIA 4/28 - - + 0 
21 F 36 Breast Invasive ductal carcinoma T2N2aM0 IIIA 7/24 - - - 2 
22 F 59 Breast Invasive ductal carcinoma T2N3bM0 IIIC 16/25 + + - 1 
23 F 34 Breast Ductal carcinoma in situ TisN0M0 0 0/5 - - + 2 
24 F 54 Breast Invasive ductal carcinoma T2N2aM0 IIIA 8/8 + + + 1 
25 F 47 Breast Invasive ductal carcinoma T2N0M0 IIA 0/22 + + - 2 
26 F 53 Breast Invasive ductal carcinoma T2N0M0 IIA 0/12 - - + 0 
27 F 59 Breast Invasive ductal carcinoma T2N1aM0 IIB 3/24 + - - 1 
28 F 60 Breast Signet ring cell carcinoma T3N0M0 IIB 0/7 + + - 1 
29 F 37 Breast Invasive ductal carcinoma T3N2aM0 IIIA 7/21 - + + 1 
30 F 46 Breast Invasive ductal carcinoma T2N0M0 IIA 0/17 + - - 0 
31 F 35 Breast Invasive ductal carcinoma T3N2aM0 IIIA 8/14 + - - 3 
32 F 47 Breast Invasive ductal carcinoma T2N0M0 IIA 0/26 - - + 3 
33 F 54 Breast Invasive ductal carcinoma T2N0M0 IIA 0/17 + + - 2 
34 F 47 Breast Invasive ductal carcinoma T2N2aM0 IIIA 8/17 - - + 3 
35 F 41 Breast Invasive ductal carcinoma T3N0M0 IIB 0/6 + + - 2 
36 F 38 Breast Invasive ductal carcinoma T3N1aM0 IIIA 2/6 - - + 2 
37 F 55 Breast Invasive ductal carcinoma T2N1aM0 IIB 3/21 - - + 2 
38 F 65 Breast Invasive ductal carcinoma T2N0M0 IIA 0/9 + - - 1 
39 M 66 Breast Invasive ductal carcinoma T3N2aM0 IIIA 5/14 - - - 3 
40 F 64 Breast Invasive ductal carcinoma T3N1aM0 IIIA 1/12 + - + 1 
41 F 52 Lymph node Metastatic invasive ductal carcinoma T3N3aM0 IIIC 10/22 - - + 3 
42 F 32 Lymph node Metastatic invasive ductal carcinoma T3N3aM0 IIIC 20/23 + + - 3 
43 F 58 Lymph node Metastatic invasive ductal carcinoma T3N3aM0 IIIC 22/22 + + + 3 
44 F 52 Lymph node Metastatic invasive ductal carcinoma T3N3M0 IIIC 24/24 - - - 3 
45 F 58 Lymph node Metastatic invasive ductal carcinoma T3N2aM0 IIIA 4/20 - - + 3 
46 F 38 Lymph node Metastatic invasive ductal carcinoma T1cN1aM0 IIA 1/8 + + - 3 
47 F 45 Lymph node Metastatic medullary carcinoma T1cN2aM0 IIIA 9/23 - - - 3 
48 F 45 Lymph node Metastatic invasive lobular carcinoma T2N3aM0 IIIC 11/20 + + - 2 
49 F 29 Lymph node Metastatic invasive ductal carcinoma T2N2aM0 IIIA 8/10 - - + 1 
50 F 61 Lymph node Metastatic invasive ductal carcinoma T1bN3aM0 IIIC 22/26 - - - 1 
51 F 46 Breast Normal, nipple       0 
52 F 47 Breast Normal, nipple       0 
53 F 40 Breast Normal       0 
54 F 43 Breast Normal       0 
55 F 40 Breast Normal       0 
56 F 40 Breast Normal       0 
57 F 45 Breast Normal       0 
58 F 44 Breast Normal       0 
59 F 37 Breast Normal       0 
60 F 51 Breast Normal       0 
 
 
 
a: LN, metastasis-positive lymph nodes / examined lymph nodes; b: ER, estrogen receptor; c: PgR, progesterone receptor; d: N/A, not applicable. 
 
Supplementary Table 2.  CYP26A1 expression and clinical profiles in patients with breast carcinoma. 
 
No. Sex Age Diagnosis pTNM Stage Prognosis Outcome Disease free 
(Month) 
Survival 
(Month) 
ERa PgRb 
 
Her2c 
 
CYP26A1 Staining pattern
1 F 56 Invasive ductal carcinoma T2N1M0 IIB Alive  76 76 + + 2 0  
2 F 47 Invasive ductal carcinoma T4N1M1 IV Alive Bone metastasis 3 76 + + 3 3 Diffuse 
3 F 79 Ductal carcinoma in situ TisN0M0 0 Alive  76 76 + + 3 0  
4 F 54 Invasive ductal carcinoma T1N0M0 I Alive  76 76 + + 2 0  
5 F 68 Invasive ductal carcinoma T2N1M0 IIB Alive  76 76 + - 2 2 Scattered 
6 F 54 Invasive ductal carcinoma T2N0M0 IIA Alive  75 75 - - 3 0  
7 F 49 Invasive ductal carcinoma T2N1M0 IIB Alive  76 76 - - 1 2 Focal 
8 F 60 Invasive ductal carcinoma T2N2M0 IIIA Alive  74 74 - - 1 2 Diffuse 
9 F 46 Invasive ductal carcinoma T2N3M0 IIIC Alive  75 75 - - 3 0  
10 F 65 Invasive ductal carcinoma T1N0M0 I Alive  77 77 + + 1 0  
11 F 53 Invasive ductal carcinoma T2N1M0 IIB Alive  76 76 - - 1 0   
12 F 73 Apocrine carcinoma T1N0M0 I Alive  77 77 - - 3 0  
13 F 73 Invasive ductal carcinoma T2N0M0 IIA Alive  78 78 + + 1 2 Diffuse 
14 F 40 Invasive ductal carcinoma T1N0M0 I Alive  76 76 - - 2 0  
15 F 58 Invasive ductal carcinoma T2N0M0 IIA Alive  77 77 - - 0 1 Focal 
16 F 50 Invasive ductal carcinoma T2N0M0 IIA Alive  73 73 + + 2 0  
17 F 52 Invasive ductal carcinoma T1N0M0 I Alive  74 74 + - 2 3 Diffuse 
18 F 73 Invasive ductal carcinoma T1N0M0 I Alive  75 75 + + 3 1 Focal 
19 F 60 Invasive ductal carcinoma T2N2M0 IIIA Death Bone metastasis 34 41 - - 1 0  
20 F 75 Invasive ductal carcinoma T4N1M0 IIIB Alive  78 78 + - 2 1 Focal 
21 F 45 Invasive ductal carcinoma T2N0M0 IIA Alive  76 76 + - 1 0  
22 F 68 Invasive ductal carcinoma T2N2M0 IIIA Death Brain metastasis 28 32 - - 2 3 Diffuse 
23 F 69 Invasive ductal carcinoma T2N0M0 IIA Alive  77 77 - - 1 0  
24 F 58 Apocrine carcinoma T2N0M0 IIA Alive  76 76 - - 1 2 Diffuse 
25 F 52 Invasive ductal carcinoma T2N0M0 IIA Alive  76 76 - - 0 2 Focal 
26 F 60 Invasive ductal carcinoma T2N1M0 IIB Alive  76 76 - - 1 0  
27 F 90 Invasive ductal carcinoma T2N3M0 IIIC Death Local recurrence 2 5 - - 1 3 Diffuse 
28 F 33 Invasive ductal carcinoma T2N0M0 IIA Alive  76 76 + + 3 1 Focal 
29 F 80 Invasive ductal carcinoma T2N0M0 IIA Death Lung metastasis 12 30 + + 2 1 Diffuse 
30 F 59 Invasive ductal carcinoma T1N0M0 I Alive  78 78 + - 3 0  
31 F 60 Invasive ductal carcinoma T2N3M0 IIIC Death Local recurrence 1 42 + + 3 3 Diffuse 
32 F 38 Invasive ductal carcinoma T1N0M0 I Alive  75 75 + + 3 0  
33 F 35 Invasive ductal carcinoma T1N0M0 I Alive  76 76 - - 3 0  
34 F 36 Invasive ductal carcinoma T1N0M0 I Alive  77 77 - - 3 0  
35 F 73 Invasive ductal carcinoma T2N3M0 IIIC Death Local recurrence 27 45 + - 3 3 Diffuse 
36 F 50 Invasive ductal carcinoma T1N0M0 I Alive  76 76 + - 2 0  
37 F 57 Invasive ductal carcinoma T2N1M1 IV Death Lung metastasis 1 3 - - 3 2 Diffuse 
38 F 62 Invasive ductal carcinoma T2N0M0 IIA Alive  77 77 + - 2 1 Scattered 
39 F 35 Invasive ductal carcinoma T1N0M0 I Alive  76 76 + - 3 0   
40 F 39 Invasive ductal carcinoma T3N3M0 IIIC Alive Bone metastasis 33 78 + - 3 2 Focal 
41 F 45 Invasive ductal carcinoma T2N0M0 IIA Alive  78 78 + - 2 0  
42 F 39 Invasive ductal carcinoma T2N0M0 IIA Alive  77 77 + + 3 2 Diffuse 
43 F 65 Invasive ductal carcinoma T1N0M0 I Alive  78 78 + + 3 0  
44 F 66 Invasive ductal carcinoma T2N0M0 IIA Alive  75 75 + + 1 3 Diffuse 
45 F 61 Invasive ductal carcinoma T3N3M0 IIIC Alive Lung metastasis 32 74 - - 0 2 Focal 
46 F 31 Invasive ductal carcinoma T2N1M0 IIB Death N/Ad 21 43 - - 3 3 Diffuse 
47 F 47 Invasive ductal carcinoma T2N3M0 IIIC Death Local recurrence 2 51 + + 3 0  
48 F 66 Invasive ductal carcinoma T2N1M0 IIB Alive Bone metastasis 58 76 + + 1 2 Diffuse 
49 F 43 Invasive ductal carcinoma T2N1M1 IV Death Lung metastasis 1 12 - - 2 2 Diffuse 
50 F 70 Mucinous carcinoma T2N0M0 IIA Alive  77 77 + + 1 0  
51 F 62 Invasive ductal carcinoma T2N3M0 IIIC Alive Bone metastasis 54 76 + + 2 2 Diffuse 
52 F 46 Invasive ductal carcinoma T1N0M0 I Alive  75 75 + + 2 0  
53 F 52 Invasive ductal carcinoma T2N1M1 IV Death Bone metastasis 1 23 - - 0 3 Diffuse 
54 F 63 Invasive ductal carcinoma T1N0M0 I Alive  77 77 + - 0 0  
55 F 64 Invasive ductal carcinoma T3N1M0 IIIA Alive  78 78 + + 0 0  
56 F 50 Invasive ductal carcinoma T4N0M0 IIIB Death Local recurrence 4 32 - - 3 3 Diffuse 
57 F 59 Invasive ductal carcinoma T2N2M0 IIIA Alive  76 76 + - 1 2 Scattered 
58 F 54 Invasive ductal carcinoma T2N1M0 IIB Death Local recurrence 4 16 + + 3 3 Diffuse 
59 F 44 Invasive ductal carcinoma T2N2M0 IIIA Alive Local recurrence 5 76 + + 2 0  
60 F 53 Invasive ductal carcinoma T2N3M0 IIIC Death N/Ad 24 25 - - - 0  
61 F 54 Invasive lobular carcinoma T4N2M0 IIIB Alive Local recurrence 54 76 - - 3 1 Focal 
62 F 55 Invasive ductal carcinoma T2N1M0 IIB Alive Local recurrence 42 77 + - 2 0  
63 F 55 Invasive ductal carcinoma T2N0M0 IIA Alive  76 76 - - 0 0  
64 F 52 Invasive ductal carcinoma T2N1N0 IIB Alive  73 73 - - 3 2 Diffuse 
65 F 50 Invasive ductal carcinoma T2N0M0 IIA Alive Local recurrence 27 76 + + 2 2 Diffuse 
 
 
a: ER, estrogen receptor; b: PgR, progesterone receptor; c: Her2 positivity scored by Hercep Test method; d: N/A, not applicable. 
 
